OB
Ollin BiosciencesClinical-stage biopharmaceutical company developing best-in-disease therapies for vision-threatening eye diseases, including a VEGF/Ang2 bispecific antibody in Phase 3 for DME and wet AMD.
2 Pulse stories
ST
Scribe TherapeuticsClinical-stage biotech developing CRISPR-based gene-editing therapeutics using its proprietary CasX enzyme platform.
5 Pulse stories
Total Raised
$430M
Ollin BiosciencesScribe Therapeutics
Last ValuationNot disclosed
Biotech
Sector
Biotech
2023
Founded
2018
Chicago, Illinois
HQ
Alameda, California
Private
Status
Public (SCTX)
Ollin Biosciences investors
ARCH Venture PartnersTCGX (TCG Crossover)Andreessen HorowitzMubadala CapitalMonograph CapitalBlackstone Multi-Asset InvestingCommodore CapitalRA Capital Management
Scribe Therapeutics investors
No investors on record.
Data from Value Add Pulse coverage and company research — see the full threads for Ollin Biosciences and Scribe Therapeutics.